Skip to main content
Login
Contact
Subscribe
Search form
Search
The Sweetwater Reporter
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Uniqure N.V.
(NQ:
QURE
)
26.36
USD
-0.32 (-1.20%)
Official Closing Price
/ Updated:
4:11 PM EDT, Oct 22, 2018
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
312,200
Open
26.66
Bid (Size)
26.35 (40)
Ask (Size)
27.00 (1)
Prev. Close
26.68
Today's Range
25.38 - 26.93
52wk Range
13.71 - 43.23
Shares Outstanding
31,683,988
Dividend Yield
N/A
Performance
YTD
+30.75%
+30.75%
1 Month
-34.57%
-34.57%
3 Month
-21.59%
-21.59%
6 Month
-15.16%
-15.16%
1 Year
+42.33%
+42.33%
Top News
More News
uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
October 18, 2018
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented non-clinical data demonstrating that a...
Read More
from
GlobeNewswire News Releases
uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 17, 2018
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today presented new data demonstrating its ability to...
Read More
from
GlobeNewswire News Releases
More News
Read More
uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
October 16, 2018
from
GlobeNewswire News Releases
uniQure to Participate in Multiple Upcoming Industry Conferences
September 28, 2018
from
GlobeNewswire News Releases
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
September 24, 2018
from
GlobeNewswire News Releases
Synpromics Promoter Technology Moves Closer to the Clinic
October 18, 2018
from
Business Wire News Releases
Achillion Appoints Paul Firuta Chief Operating Officer
September 10, 2018
from
GlobeNewswire News Releases
uniQure to Participate at Multiple Upcoming Conferences
August 30, 2018
from
GlobeNewswire News Releases
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
August 23, 2018
from
GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcomi
August 21, 2018
from
GlobeNewswire News Releases
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
August 08, 2018
from
GlobeNewswire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
